Drug Topics
OCTOBER 22, 2024
A discussion with Madison Irwin, PharmD, BCPS, clinical pharmacist specialist in palliative care at University of Michigan Health and clinical assistant professor at the University of Michigan College of Pharmacy.
Fierce Pharma
OCTOBER 25, 2024
Despite recent concerns from the FDA about potential off-label use and antimicrobial resistance, Dublin-based Iterum Therapeutics has scored a green light for its oral antibiotic sulopenem. | Iterum's Orlynvah was approved by the FDA Friday to treat certain uncomplicated urinary tract infections (uUTIs) in adult women who have limited or no alternative antibacterial treatment options.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
OCTOBER 23, 2024
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
Fierce Healthcare
OCTOBER 24, 2024
Medicare Advantage (MA) insurers, namely industry titans UnitedHealth Group and Humana, could be using health risk assessments and chart reviews to inflate payments from Medicare through upcoding, | A federal watchdog is questioning whether UnitedHealthcare, Humana and other Medicare Advantage payers are either creating diagnoses out of thin air to inflate payments from Medicare or are not providing adequate care to sick members.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
OCTOBER 23, 2024
A study found that children aged 6 months or younger who are not eligible for vaccination were at the highest risk for hospitalization due to SARS-CoV-2.
Fierce Pharma
OCTOBER 23, 2024
The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent | Novo Nordisk has asked the FDA to prevent compounders from manufacturing copycat versions of its juggernaut diabetes and obesity treatments Ozempic and Wegovy, claiming the drugs are too complex to safely replicate.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
pharmaphorum
OCTOBER 22, 2024
Otsuka is hoping to file for approval of its anti-APRIL antibody sibeprenlimab as a treatment for kidney disorder IgA nephropathy (IgAN) after the drug hit the target in a phase 3 trial.The Japanese drugmaker said that interim results from the 530-patient VISIONARY study showed that sibeprenlimab achieved a statistically significant and clinically meaningful reduction in 24-hour urine protein-to-creatine ratio (uPCR) – a measure of how well the kidneys are working – after nine months of treatmen
Drug Topics
OCTOBER 23, 2024
New research presented at AMCP Nexus 2024 highlighted the effectiveness and cost-effectiveness of various migraine treatments, including onabotulinumtoxinA and fremanezumab, as well as the importance of migraine education programs for improving patient outcomes.
Fierce Pharma
OCTOBER 22, 2024
Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. | Pfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. The layoffs come three months after the company axed 150 positions in Sanford following a high-profile phase 3 trial failure for its Duchenne muscular dystrophy gene therapy candidate.
PharmaVoice
OCTOBER 22, 2024
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 24, 2024
The FDA announces a Class II recall for the lot #220128, which were reported to contain the presence of nitrosamine.
Drug Topics
OCTOBER 25, 2024
As the H5 bird flu outbreak gradually impacts human health in the US, health care experts weighed in on possibilities of a future vaccine.
Fierce Pharma
OCTOBER 23, 2024
While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. | Amgen is preparing to launch its Eylea biosimilar, Pavblu, after another victory over Regeneron in court. That said, Regeneron is appealing the decision and stressed that it continues to believe Amgen's copycat infringes multiple Eylea patents.
PharmaVoice
OCTOBER 24, 2024
Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
OCTOBER 23, 2024
Pharmacists can educate patients about how to recognize unsafe online sources of medications and ensure patients are properly educate on how to administer their medications.
Drug Topics
OCTOBER 21, 2024
Suzetrigine could represent the first new nonopioid drug in a distinct class of pain medications in approximately 20 years.
Fierce Pharma
OCTOBER 23, 2024
While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the | While Novo Holdings and Catalent continue to voice confidence that their planned $16.5 billion merger will go through before the year is out, the deal has received near-constant criticism over the past several weeks.
PharmaVoice
OCTOBER 21, 2024
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Healthcare
OCTOBER 21, 2024
LAS VEGAS—Health tech companies CopilotIQ and Biofourmis announced a strategic merger on Monday that combines tech-enabled in-home care solutions from pre-surgical optimization to acute, post-acute | Health tech companies CopilotIQ and Biofourmis announced a strategic merger on Monday that combines tech-enabled in-home care solutions from pre-surgical optimization to acute, post-acute and chronic care.
Drug Topics
OCTOBER 22, 2024
Analyzing copayments and coverage plans for popular weight-loss drugs in the US, researchers addressed the cost-effectiveness of GLP-1 medications for treating obesity.
Pharmacy Times
OCTOBER 23, 2024
Pharmacists will likely be the first contact for many affected patients, and they should be able to provide evidence-based advice on how to manage their infection.
PharmaVoice
OCTOBER 22, 2024
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
STAT
OCTOBER 25, 2024
For the nation’s largest health insurer, the evidence of abuse was stunning and unmistakable: UnitedHealth Group reaped billions from the federal Medicare program by diagnosing patients with serious chronic illnesses, and then delivering no follow-up care. The findings in the federal report reveal that UnitedHealth repeatedly sent clinicians into patients’ homes and pored over their medical charts to add diagnoses for illnesses such as vascular disease, heart failure, and diabetes.
Drug Topics
OCTOBER 21, 2024
Opioid use disorder risk was higher in a cohort of patients with chronic pain without disability.
Pharmacy Times
OCTOBER 21, 2024
The story of pinksocks and the inspiring movement that they launched.
The Guardian - Pharmaceutical Industry
OCTOBER 24, 2024
Biotech giant’s alleged comments come as world leaders at Cop16 discuss how to share benefits from genetic code discoveries fairly AstraZeneca has said it may cut jobs at its UK operation if the government enforces a global push to make companies share profits derived from nature’s genetic codes, multiple sources have told the Guardian. The alleged comments from the company came amid a concerted lobbying push by the pharmaceutical industry against the profit-sharing measures.
STAT
OCTOBER 24, 2024
Imagine, for a moment, that you wake up one morning with a debilitating illness that won’t let go. Weeks and months pass, but the crushing fatigue, constant headaches, and aching muscles remain. You can’t think straight. Simply showering or doing the dishes leaves you floored for days at a time, and the unpredictable symptoms — shortness of breath, dizziness, a racing heart — ebb and flow without warning.
Drug Topics
OCTOBER 24, 2024
Adding to the mail-order options within big chain pharmacy, Walmart is promising prescription delivery in as quickly as 30 minutes.
Pharmacy Times
OCTOBER 25, 2024
Their expertise complements multidisciplinary teams in a variety of clinical settings.
The Guardian - Pharmaceutical Industry
OCTOBER 23, 2024
‘Surprising’ finding by Australian-led study is first recorded instance of one antibiotic causing resistance to another in a different class Follow our Australia news live blog for latest updates Get our breaking news email , free app or daily news podcast The rise of an almost untreatable superbug has been linked to a common antibiotic, an Australian-led study has found.
STAT
OCTOBER 24, 2024
A federal watchdog found that Medicare Advantage insurers collected billions of dollars in dubious payments from Medicare in a single year by using home visits and medical chart reviews to diagnose patients with conditions for which they received no follow-up care. A report released Thursday by the Office of Inspector General for the Health and Human Services Department concluded that insurers collectively received an estimated $7.5 billion in payments last year from so-called
Drug Topics
OCTOBER 23, 2024
Researchers addressed the association between sleep patterns and digestive diseases, as well as patients’ genetic likeliness of developing future digestive complications.
Pharmacy Times
OCTOBER 22, 2024
In April 2024, the FDA approved ustekinumab-aekn as a subcutaneous injection for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis.
Expert insights. Personalized for you.
603 
Let's personalize your content